Related Experiment Video

Updated: Jun 28, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Loss of confidence in diabetes management

Patricia R Salber1, William Bestermann, Stanley Schwartz

  • 1PRS Healthcare Consulting, Larkspur, California, USA.

Managed Care (Langhorne, Pa.)
|November 11, 2008
PubMed
Abstract

Insights

Current type 2 diabetes treatments often fail, leading to complications. Aggressive interventions targeting insulin resistance and cell dysfunction, alongside a shift towards wellness in managed care, could improve patient outcomes and offer economic benefits.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Public Health

Background:

  • Many patients with type 2 diabetes (T2D) do not reach glycemic targets with current therapies.
  • Existing treatments are associated with significant macrovascular complications, increasing morbidity and mortality.

Purpose of the Study:

  • To explore alternative therapeutic strategies for type 2 diabetes management.
  • To evaluate the potential impact of aggressive interventions on patient outcomes and healthcare economics.

Main Methods:

  • This study reviews current treatment paradigms and proposes a shift in therapeutic focus.
  • It examines the role of addressing insulin resistance and beta-cell dysfunction.
  • The potential of value-based insurance design in optimizing diabetes care is considered.

Main Results:

  • Current approaches are insufficient for optimal glycemic control and complication prevention in T2D.
  • Aggressive therapeutic interventions targeting underlying pathophysiology show promise in altering disease trajectory.
  • Managed care organizations face challenges in current diabetes management models.

Conclusions:

  • A paradigm shift towards aggressive interventions addressing insulin resistance and cell dysfunction is warranted.
  • Managed care organizations should prioritize wellness and consider value-based insurance design for improved T2D outcomes.
  • Optimizing diabetes management can lead to better patient health and economic advantages for healthcare systems.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...